Shares of HIMS surged 10.3% to $25.88 on volume of 107.0 million shares, marking an extreme intraday move for the telehealth platform. The stock rallied without an immediate earnings catalyst or major filing disclosed in public data.
The company most recently reported Q4 2025 results showing EPS of $0.08, beating the $0.04 consensus estimate. Revenue for that quarter reached $617.8 million. The prior quarter, Q3 2025, delivered EPS of $0.06 on revenue of $599.0 million.
No specific catalyst was immediately identified for today’s price surge. HIMS operates in the specialty pharmaceutical sector, offering direct-to-consumer health and wellness products across chronic conditions including hormone health, weight loss, and dermatology. The stock’s move comes ahead of Q2 2026 results, for which analysts expect EPS of $0.13 on revenue of $616.5 million.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.